Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 1,694 trials

Advanced Breast Cancer: Elacestrant and Everolimus Study

We are studying a combination of elacestrant and everolimus for patients with advanced breast cancer that has specific mutations. The goal is to see if this treatment helps delay cancer progression compared to a placebo.

Advanced Estrogen Receptor-Positive Breast Cancer1-2 yearsConfirmation phase (III)Investigational MedicinesEndocrinologyOncology

Recurrent Lower Respiratory Tract Infections: Buccalin Tablets

We are studying Buccalin tablets to see if they can help prevent recurrent lower respiratory tract infections. This trial aims to gather more information on their safety and effectiveness.

Recurrent Lower Respiratory Tract InfectionsMonitoring phase (IV)16-20 visitsStandard MedicinesInternal MedicinePulmonology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

B-Cell Non-Hodgkin Lymphoma: BI-1206 Treatment Study

We are studying a new monoclonal antibody combined with rituximab, with or without acalabrutinib, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The goal is to assess safety and how well it may work in reducing cancer cells.

Indolent B-Cell Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Gastric Cancer: New Drug Combinations

We are studying whether a new combination of trifluridine/tipiracil and oxaliplatin, with or without nivolumab, is more effective than standard treatment for patients with advanced gastric or esophageal cancer. The goal is to improve survival and quality of life for those with HER2 negative cancer.

HER2 Negative Gastric CancerEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Prednisone for Idiosyncratic Hepatotoxicity

We are studying whether prednisone can help reduce liver damage in patients with idiosyncratic hepatotoxicity. The trial will also assess its safety and impact on quality of life compared to a placebo.

Liver Toxicity>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHepatologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Major Depression: Samyr® Tablet Study

We are investigating whether Samyr® tablets can improve symptoms in patients with major depressive disorder who are not fully responding to their current treatment. The study compares Samyr® to a placebo to assess its effectiveness and safety.

Major Depression Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemotePsychiatry

Mucosal Melanoma: Anti-PD1 Immunotherapy Study

We are investigating whether a new treatment combining anti-PD1 therapy with surgery improves disease-free survival in patients with resectable mucosal melanoma. This study aims to evaluate the effectiveness and safety of this approach.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteDermatologyOncology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Psychosis in Alzheimer's: ITI-1284 Study

We are evaluating a new medication, ITI-1284, for treating psychosis in patients with Alzheimer's disease. The study aims to see if it is more effective than a placebo in improving symptoms.

Psychosis associated with Alzheimer’s Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Bipolar Mania: Lumateperone Study

We are evaluating the safety and effectiveness of lumateperone for treating manic episodes in patients with bipolar I disorder. This study compares the medication to a placebo to see how well it works.

Bipolar Disorder≤3 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPsychiatry

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Acute Myeloid Leukemia: Sulfasalazine with Chemotherapy

We are studying the addition of sulfasalazine to standard chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. The goal is to evaluate safety and effectiveness compared to existing treatments.

Acute Myeloid Leukemia>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Cryptogenic Stroke: STOP Trial on Blood Thinners

We are studying whether stopping blood thinners is as safe as continuing them for young people after a stroke with no known cause. This research may help understand the best approach to prevent future heart problems.

Stroke>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

MEN1703 for Aggressive B-cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of MEN1703 alone and with glofitamab in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. This research aims to find better treatment options for this challenging cancer.

Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Vaginal Progesterone for Fertility: Standard vs. New Formulation

We are comparing two formulations of vaginal progesterone to see which one better supports pregnancy in women undergoing fertility treatments. This study aims to improve pregnancy rates and assess safety for participants.

Infertility>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesEndocrinologyGynecology and Obstetrics

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology